Novavax: Sell The Covid Rips

May 24, 2023 3:17 PM ETNovavax, Inc. (NVAX) StockMRNA, PFE, NVAX33 Comments

Summary

  • Novavax, Inc. continues to rally on positive Covid news, but the vaccine demand continues to trend lower.
  • The biotech now plans to slash operating expenses by up to 50% from 2022 levels in a further sign vaccine sales are cratering.
  • Novavax, Inc. stock remains a sell after the company burned nearly $350 million in cash during Q1'23 and the company remains a third wheel in the Covid vaccine sector.
  • Looking for more investing ideas like this one? Get them exclusively at Out Fox The Street. Learn More »

Germany Begins Novavax Covid Vaccinations

Carsten Koall

Novavax, Inc. (NASDAQ:NVAX) continues to pop on positive vaccine news whether related to sales numbers or Covid infections around the globe. The biotech is struggling to figure out how to make the vaccine sales profitable while

If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market heading into a 2023 Fed pause, consider joining Out Fox The Street

The service offers model portfolios, daily updates, trade alerts and real-time chat. Sign up now for a risk-free, 2-week trial to start finding the next stock with the potential to generate excessive returns in the next few years without taking on the out sized risk of high flying stocks. 

This article was written by

52.49K Followers

Stone Fox Capital is an RIA from Oklahoma. Mark Holder is a CPA with degrees in Accounting and Finance. He is also Series 65 licensed and has 30 years of investing experience, including 15 years as a portfolio manager.

Mark leads the investing group

Out Fox The Street

where he shares stock picks and deep research to help readers uncover potential multibaggers while managing portfolio risk via diversification. Features include various model portfolios, stock picks with identifiable catalysts, daily updates, real-time alerts, and access to community chat and direct chat with Mark for questions.

Learn more

.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock, you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About NVAX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on NVAX

Related Stocks

SymbolLast Price% Chg
NVAX
--